Radiopharm Theranostics Launches US$4.1M Direct Offering and Up to A$12.7M Australian Placement, Totaling ~US$17.7M
RADX sits 19% above its 52-week low of $3.62.
Summary
Radiopharm Theranostics announced a concurrent US$4.1 million registered direct offering and up to A$12.7 million Australian placement and share purchase plan, raising up to ~US$17.7 million to fund clinical development.
Key Events · Financing and Capital Events · RADX
-
US$4.1M Direct Offering at Discount
The company is issuing 1,281,646 ADSs at US$3.16 per ADS, a 26% discount to the current US$4.29 price, raising US$4.1 million before fees.
-
Warrants Attached to US Offering
Investors receive unregistered warrants to purchase up to 1,281,646 ADSs at US$3.79, exercisable after shareholder approval, expiring July 2029.
-
Australian Placement and Share Purchase Plan
Up to A$12.7 million (US$8.9 million) could come from an Australian placement (A$6.7M firm commitments) and a share purchase plan (up to A$6M), with options at A$0.018.
-
Total Potential Raise ~US$17.7M
Combined US and Australian components could bring in up to US$17.7 million, significantly extending the cash runway for clinical programs.
Analysis · RADX · Life Sciences
To fund its next clinical milestones, Radiopharm Theranostics is tapping the market for up to US$17.7 million through a multi-pronged offering. The package includes a US$4.1 million registered direct offering of ADSs priced at US$3.16—a 26% discount to the current US$4.29—alongside up to A$12.7 million (US$8.9 million) from an Australian placement and share purchase plan. The deep discount and attached warrants and options signal an urgent need for capital, but the proceeds are earmarked for a registrational study and other clinical work, which is critical for a clinical-stage biotech. Coming just two days after positive Phase 2b data, the raise suggests the company is seizing the momentum to extend its runway. While a concurrent ATM program filed yesterday adds to the dilution overhang, this direct raise locks in immediate cash.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $4.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.9M. The 52-week trading range was $3.62 to $16.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.